Global Healthcare Contract Development & Manufacturing Organization Market Report 2020-2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Healthcare Contract Development & Manufacturing Organization Market (2020-2025) by services Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.

The Global Healthcare Contract Development & Manufacturing Organization Market is estimated to be USD 193 Bn in 2020 and is expected to reach USD 286 Bn by 2025, growing at a CAGR of 8.2 %.

Market Dynamics

Key factors, such as the growing number of new molecular entities have led to a demand for high-end technical expertise. Also, at given times, to expedite the drug manufacturing process, pharma companies are depending on CDMOs for their niche technical expertise to get the product in the market. In addition to it, companies are equally focusing on reducing the capital expenditure involved in manufacturing processes. These factors are prominently driving the growth of the contract development and manufacturing organization (CDMO) market.

However, the serialization issues along with the infringement issues related to intellectual property are likely to restrain the market growth.

Recent Developments

1. Moderna, Inc and Recipharm AB, a CDMO have drafted an agreement to support the formulation and fill-finish a part of the Moderna COVID-19 Vaccine supply outside the U.S. – 30th December 2020

2. Siegfried has acquired two pharmaceutical manufacturing sites from Novartis based out of Spain. This is in view towards creating a center of excellence for the sites’ current technology portfolio in the Barcelona region.- 29th September 2020

Company Profiles

Some of the companies covered in this report are Lonza Group Ltd.; Recipharm AB; Siegfried Holding AG; Covance Inc.; Jabil; Sanmina Corporation; IQVIA Holdings Inc.; and Flex.

Key Topics Covered:

1 Report Description

1.1 Study Objectives

1.2 Market Definition

1.3 Currency

1.4 Years Considered

1.5 Language

1.6 Key Shareholders

2 Research Methodology

2.1 Research Process

2.2 Data Collection and Validation

2.3 Market Size Estimation

2.4 Assumptions of the Study

2.5 Limitations of the Study

3 Executive Summary

4 Market Overview

4.1 Introduction

4.2 Market Dynamics

4.2.1 Drivers

4.2.1.1 Need of a high-level expertise to expedite drug manufacturing process

4.2.1.2 Focus of the pharmaceutical companies towards reducing their operational expenses

4.2.1.3 Increasing complexity with the development of new molecular entities

4.2.2 Restraints

4.2.2.1 Serialization issues faced by healthcare organizations

4.2.2.2 Issues related to infringement of Intellectual Property (IP) rights

4.2.3 Opportunities

4.2.3.1 Rise in the drug approvals cases

4.2.3.2 Technological Advancements

4.2.3.3 Increasing collaborations and investments by CDMOs

4.2.4 Challenges

4.2.4.1 Compliance issues while outsourcing

4.3 Trends

5 Market Analysis

5.1 Porter’s Five Forces Analysis

5.2 Impact of COVID-19

5.3 Ansoff Matrix Analysis

6 Global Healthcare Contract Development & Manufacturing Organization Market, By Service

6.1 Introduction

6.2 Contract Development

6.2.1 Preclinical

6.2.1.1 Bioanalysis and DMPK studies

6.2.1.2 Toxicology Testing

6.2.1.3 Other Preclinical Services

6.2.2 Clinical

6.2.2.1 Phase I

6.2.2.2 Phase II

6.2.2.3 Phase III

6.2.2.4 Phase IV

6.2.3 Laboratory Services

6.2.3.1 Bioanalytical Services

6.2.3.2 Analytical Services

6.3 Contract Manufacturing

6.3.1 API/Bulk Drugs

6.3.2 Finished Dose Formulations

6.3.3 Medical Device

6.3.3.1 Class I

6.3.3.2 Class II

6.3.3.3 Class III

7 Global Healthcare Contract Development & Manufacturing Organization Market, By Solution Type

8 Competitive Landscape

8.1 IGR Competitive Quadrant

8.2 Market Share Analysis

8.3 Competitive Scenario

8.3.1 Mergers & Acquisitions

8.3.2 Agreement, Collaborations, & Partnerships

8.3.3 New Product Launches & Enhancements

8.3.4 Investments & Fundings

9 Company Profiles

9.1 AbbVie Inc.

9.2 Almac Group Ltd.

9.3 Baxter International, Inc.

9.4 B. Braun Melsungen AG

9.5 Boehringer Ingelheim International GmbH

9.6 Catalent Inc.

9.7 Covance Inc.

9.8 Cambrex Corp. (Permira Funds)

9.9 Hisun Pharmaceuticals Inc.

9.10 Jabil Inc.

9.11 Jubilant Life Sciences Ltd.

9.12 IQVIA Holdings Inc

9.13 Flex

9.14 Lonza Group Ltd.

9.15 Mikart LLC (Nautic Partners)

9.16 Pfizer Inc.

9.17 Probiogen AG (Minapharm Pharmaceuticals)

9.18 Recipharm AB

9.19 Siegfried Holding AG

9.20 Sanmina Corp.

9.21 Stason Pharmaceuticals, Inc.

9.22 Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/qoloyr

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900